PolyPid Ltd. filed its interim financial statements for the six months ended June 30, 2026, reporting a net loss of $15.6 million and cash reserves of $6.6 million. The company entered into a license and supply agreement with Azurity Pharmaceuticals on July 17, 2026, granting exclusive U.S. and Canadian commercialization rights to its product D-PLEX 100 in exchange for a $15 million upfront payment and up to $290 million in potential milestones. PolyPid operates as an innovative biopharmaceutical company developing long-acting controlled-release medicines.

PolyPid Ltd. reported second quarter 2026 financial results and announced that the FDA accepted its New Drug Application for D-PLEX₁₀₀ with Priority Review, setting a PDUFA goal date of November 28, 2026. The company entered an exclusive U.S. and Canada commercialization partnership with Azurity Pharmaceuticals, achieving $30 million in upfront and near-term milestone payments following NDA acceptance, with potential total milestones up to approximately $320 million plus tiered royalties. For the three months ended June 30, 2026, PolyPid reported a net loss of $7.8 million ($0.35 per share) compared to $10.0 million in the prior year period. As of June 30, 2026, cash and cash equivalents were $6.6 million. The company operates as an innovative biopharmaceutical firm developing long-acting, controlled-release drugs for surgical care and metabolic diseases.

PolyPid announced that the U.S. Food and Drug Administration accepted its New Drug Application for D-PLEX 100 with Priority Review status, setting a PDUFA target action date of November 28, 2026. This acceptance triggers a $15 million milestone payment from commercial partner Azurity Pharmaceuticals, completing the $30 million in upfront and near-term payments under their July 17, 2026 partnership agreement. The Priority Review designation shortens the FDA review timeline to approximately six months, accelerating the potential U.S. launch by early 2027. PolyPid is an innovative biopharmaceutical company developing long-acting, controlled-release drugs for surgical care and metabolic diseases.

PolyPid Ltd. entered into an exclusive License and Supply Agreement with Azurity Pharmaceuticals Ireland Ltd. on July 17, 2026, for the commercialization of D-PLEX 100 in the United States and Canada. The agreement includes a $15 million upfront payment and a $15 million near-term milestone payment upon FDA acceptance of the New Drug Application, which is expected in August 2026. PolyPid is eligible for up to $300 million in additional milestone payments and tiered royalties between mid-teen and mid-twenties percentages. PolyPid is a biopharmaceutical company that develops long-acting, controlled-release drugs for surgical care and metabolic diseases.

PolyPid Ltd. held an Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where shareholders approved the re-election of Kost Forer Gabbay & Kasierer as independent auditors, the re-election of eight board members, and amendments to non-executive director option grants and CEO Dikla Czaczkes Akselbrad's option grant. Additionally, the company disclosed that its Board of Directors approved an increase in the 2012 Share Option Plan pool by 1,500,000 ordinary shares, raising the total reserved shares from 3,512,403 to 5,012,403. PolyPid Ltd. is a medical technology company focused on developing products for mucosal tissue repair.